60 likes | 69 Views
Jack Kavanaugh began his distinctive career as a highly successful dentist. A major skiing accident in which he broke his neck and shattered his leg, prevented him from practicing dentistry again. From this turning point, Kavanaugh went on to earn his M.B.A. from U.C.L.A., then worked in mergers and acquisitions with a former partner who had been managing director / senior partner at McKenzie International. <br>
E N D
Dr.Jack Kavanaugh Healthcare Professional and Entrepreneur
Jack Kavanaugh - Distinctive Career as a Highly Successful Dentist Jack Kavanaugh began his distinctive career as a highly successful dentist. A major skiing accident in which he broke his neck and shattered his leg, prevented him from practicing dentistry again. From this turning point, Kavanaugh went on to earn his M.B.A. from U.C.L.A., then worked in mergers and acquisitions with a former partner who had been managing director / senior partner at McKenzie International. In 1984, they formed International Strategy Consulting Group a management and M.B.A. consulting firm.
Dr. Kavanaugh Designated a New CEO Jack Kavanaugh continued in private equity and in 2000 held the first board meeting of Calhoun Vision, Inc. a biotechnology firm that developed the world’s first and only light adjustable intraocular lens for cataract surgery, at his home. He served as a board member from 2000 and then served as Chairman from 2008 to 2012. In 2008..
Dr. Kavanaugh Extend to the Developing Energy Field Jack Kavanaugh continued in private equity and in 2000 held the first board meeting of Calhoun Vision, Inc. a biotechnology firm that developed the world’s first and only light adjustable intraocular lens for cataract surgery, at his home. He served as a board member from 2000 and then served as Chairman from 2008 to 2012. In 2008.
Dr. Kavanaugh’s Business Accomplishments Dr. Jack Kavanaugh as CEO and Chairman of ZetaRx Biosciences, Inc, he successfully combined the intellectual property from three globally-recognized health care and research institutions, assembled a highly respected management team, and lead the development of the FDA clinical trial strategy. In late 2013, ZetaRx was sold, becoming the core of Juno Therapeutics, which went on to have the largest biotech IPO of 2014, attaining a market cap of approximately $6 billion. Recently, Juno reported 91% clinical trial complete remission of terminal cancer patients treated with their immunotherapy. In January 2018, Celgene announced a $9 billion deal to purchase 90% of Juno Therapeutics.
Dr. JACK KAVANAUGH CONTACT DETAIL • 12100 Wilshire Boulevard • Los Angeles, Colorado 90025 • United States